Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

209 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Twelve years after: The french national network on rare head and neck tumours (REFCOR).
Gasne C, Atallah S, Dauzier E, Thariat J, Fakhry N, Verillaud B, Classe M, Vergez S, Moya-Plana A, Costes-Martineau V, Righini C, de Gabory L, Digue L, Dupin C, Ferrand FR, Even C, Baujat B; REFCOR members. Gasne C, et al. Among authors: even c. Oral Oncol. 2024 Apr;151:106762. doi: 10.1016/j.oraloncology.2024.106762. Epub 2024 Mar 20. Oral Oncol. 2024. PMID: 38513311 Free article.
Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma.
Ou D, Blanchard P, El Khoury C, De Felice F, Even C, Levy A, Nguyen F, Janot F, Gorphe P, Deutsch E, Temam S, Tao Y. Ou D, et al. Among authors: even c. Oral Oncol. 2016 Nov;62:114-121. doi: 10.1016/j.oraloncology.2016.10.011. Epub 2016 Oct 22. Oral Oncol. 2016. PMID: 27865364
Long-term response in patient with recurrent oropharyngeal carcinoma treated with cetuximab, docetaxel and cisplatin (TPEx) as first-line treatment followed by cetuximab maintenance.
Guigay J, Even C, Mayache-Badis L, Debbah M, Saada-Bouzid E, Tao Y, Deschamps F, Janot F, Lezghed N, Michel C. Guigay J, et al. Among authors: even c. Oral Oncol. 2017 May;68:114-118. doi: 10.1016/j.oraloncology.2017.03.009. Epub 2017 Mar 24. Oral Oncol. 2017. PMID: 28347701
[New developments in the management of nasopharyngeal carcinoma].
Blanchard P, Nguyen F, Moya-Plana A, Pignon JP, Even C, Bidault F, Temam S, Ruffier A, Tao Y. Blanchard P, et al. Among authors: even c. Cancer Radiother. 2018 Oct;22(6-7):492-495. doi: 10.1016/j.canrad.2018.06.003. Epub 2018 Aug 4. Cancer Radiother. 2018. PMID: 30087054 Review. French.
Prognostic factors in patients with soft palate squamous cell carcinoma.
Schernberg A, Canova C, Blanchard P, Gorphe P, Breuskin I, Mirghani H, Moya-Plana A, Janot F, Bidault F, Chargari C, Bellefqih S, Ruffier A, Even C, Nguyen F, Temam S, Tao Y. Schernberg A, et al. Among authors: even c. Head Neck. 2019 May;41(5):1441-1449. doi: 10.1002/hed.25598. Epub 2019 Jan 12. Head Neck. 2019. PMID: 30636178
New approaches in salivary gland carcinoma.
Even C, Baste N, Classe M. Even C, et al. Curr Opin Oncol. 2019 May;31(3):169-174. doi: 10.1097/CCO.0000000000000527. Curr Opin Oncol. 2019. PMID: 30844885 Review.
Circulating Tumor Cells as a Prognostic Factor in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: The CIRCUTEC Prospective Study.
Garrel R, Mazel M, Perriard F, Vinches M, Cayrefourcq L, Guigay J, Digue L, Aubry K, Alfonsi M, Delord JP, Lallemant B, Even C, Daurès JP, Landais P, Cupissol D, Alix-Panabières C. Garrel R, et al. Among authors: even c. Clin Chem. 2019 Oct;65(10):1267-1275. doi: 10.1373/clinchem.2019.305904. Epub 2019 Aug 6. Clin Chem. 2019. PMID: 31387885
209 results